Tasigna is a drug that is most commonly used to treat Philadelphia chromosome-positive chronic myeloid leukemia. “Philadelphia” refers to the “Philadelphia,” or “Ph” chromosome, which determines if an individual has the condition or not. Numerous studies have shown that Tasigna can have serious, life-threatening side-effects that patients may not have been adequately warned about.
The studies show that the side effects of Tasigna can include atherosclerosis, a thickening of the arterial walls. In turn, this can develop into peripheral arterial disease (PAD), because as artery walls thicken and narrow, they become more susceptible to infection and tissue death. This can result in coronary artery disease, limbs requiring amputation, stroke, and death.
Tasigna is the brand name for nilotinib, a protein-tyrosine kinase inhibitor. The drug works by blocking chemical enzymes in cancer cells that trigger cell growth and division. It is one of the most popular cancer drugs, but nonetheless Tasinga comes with serious side effects.
It was approved by the U.S. Food and Drug Administration with a “Black Box” warning, which is the most serious classification of drug side-effects, warning of extremely severe side effects.
Allegedly, the Swiss company that manufactures and sells the drug, Novartis International AG, has known about the serious risks of the drug…